Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06084416 · ClinicalTrials.gov registry record · Phase 1
A Study of Sovilnesib in Subjects With Ovarian Cancer
A Phase 1 study of Fallopian Tube Cancer and Primary Peritoneal Carcinoma, sponsored by Volastra Therapeutics.
- Active
- Registry status
- Phase 1
- Development phase
- 120
- Enrollment target
- 13
- Study locations
NCT06084416 is a Phase 1 study of Fallopian Tube Cancer and Primary Peritoneal Carcinoma that is active but no longer recruiting, run by Volastra Therapeutics. The registered enrollment target is 120 participants, below the 254-participant average among 85 other Fallopian Tube Cancer trials with a reported enrollment target (53% lower). The trial reports 13 study locations across 11 states.
The verdict
NCT06084416, a Phase 1 study of Fallopian Tube Cancer and Primary Peritoneal Carcinoma, is active but no longer recruiting, sponsored by Volastra Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 120 participants
- Enrollment target
- 13
- Study locations
Study Summary
This is a randomized, phase 1b study to assess the safety, tolerability, pharmacokinetics (PK), and efficacy of sovilnesib at different dose levels to establish the Recommended Phase 2 Dose (RP2D) of sovilnesib in subjects with high grade serous ovarian cancer (HGSOC).
Conditions Studied
Interventions
- DRUG Sovilnesib
Study Locations (13)
California
- UCLA - Los Angeles
- Hoag Memorial Hospital - Newport Beach
New York
- Roswell Park Comprehensive Cancer Center - Buffalo
- Icahn School of Medicine at Mount Sinai - New York
Alabama
- The University of Alabama at Birmingham - Birmingham
Arkansas
- University of Arkansas for Medical Sciences - Little Rock
Georgia
- Georgia Cancer Center Augusta University - Atlanta
Maryland
- Johns Hopkins Hospital - Baltimore
Massachusetts
- Dana Farber Cancer Institute - Boston
Michigan
- Corewell Health - Grand Rapids
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2024-04-04 |
| Est. Completion | 2026-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06084416
The ClinicalTrials.gov registry entry for NCT06084416 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 254-participant average among 85 other Fallopian Tube Cancer trials with a reported enrollment target (53% lower). The listed sponsor is Volastra Therapeutics, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Fallopian Tube Cancer appearing as the primary indexed condition, and to 1 intervention - of which Sovilnesib is the first listed.
NCT06084416 reports 13 study locations spanning 11 distinct geographic areas - top geographies include California, New York, Alabama.
Frequently Asked Questions
What is clinical trial NCT06084416 about?
NCT06084416 is a clinical study titled "A Study of Sovilnesib in Subjects With Ovarian Cancer". This is a randomized, phase 1b study to assess the safety, tolerability, pharmacokinetics (PK), and efficacy of sovilnesib at different dose levels to establish the Recommended Phase 2 Dose (RP2D) of sovilnesib in subjects with high grade serous ovarian cancer (HGSOC).
What is the current status of trial NCT06084416?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 120 participants. The study started on 2024-04-04. Estimated completion is 2026-04.
What conditions does trial NCT06084416 study?
This clinical trial studies the following conditions: Fallopian Tube Cancer, Primary Peritoneal Carcinoma, High Grade Serous Adenocarcinoma of Ovary, Chromosomal Instability.
What interventions are being tested in trial NCT06084416?
The interventions under investigation include: Sovilnesib (DRUG).
Who is sponsoring clinical trial NCT06084416?
This trial is sponsored by Volastra Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06084416 being conducted?
This trial has 13 study locations across Alabama, Arkansas, California, Georgia, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Fallopian Tube Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of AVZO-021 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer
RECRUITING · Phase 1
-
Cirtuvivint/Olaparib in Breast Cancer Susceptibility Gene/Homologous Recombination Deficiency Platinum Resistant Ovarian Cancer
RECRUITING · Phase 1
-
A Study to Learn if 27T51, a Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy, Administered Alone or in Combination is Safe and How Well it Works for Adult Participants With Recurrent or Treatment Resistant Ovarian Cancers
RECRUITING · Phase 1
-
A Study of ZN-c3 in Patients With Ovarian Cancer
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.